Crossmark

Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial

Crossref DOI link: https://doi.org/10.1136/rmdopen-2023-003550

Published Online: 2023-11-09

Published Print: 2023-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Chandran, Vinod

Malkov, Vladislav A

Ito, Kaori L https://orcid.org/0000-0001-6380-6755
Liu, Yihua

Vestergaard, Lene

Yoon, Oh Kyu

Liu, Jinfeng

Trivedi, Mona

Hertz, Angie

Gladman, Dafna https://orcid.org/0000-0002-9074-0592
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03101670 at ClinicalTrials.gov

Documents that mention this clinical trial

POS1037 CORRELATION BETWEEN SKIN INVOLVEMENT, JOINT INVOLVEMENT AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POST-HOC ANALYSIS OF EQUATOR/EQUATOR2
https://doi.org/10.1136/annrheumdis-2021-eular.883

SAT0373 EFFECT OF FILGOTINIB ON PATIENT-REPORTED OUTCOMES IN ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY
https://doi.org/10.1136/annrheumdis-2019-eular.6108

FRI0343 EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR)
https://doi.org/10.1136/annrheumdis-2020-eular.2495

Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial
https://doi.org/10.1136/rmdopen-2023-003550

OP0109 EFFICACY OF FILGOTINIB VS PLACEBO IN ACTIVE PSORIATIC ARTHRITIS: PATIENT-LEVEL DATA FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY
https://doi.org/10.1136/annrheumdis-2019-eular.6064

THU0031 FILGOTINIB TREATMENT PROVIDES RAPID AND SUSTAINED REDUCTION OF INFLAMMATORY BIOMARKERS IN MODERATE TO SEVERE PSORIATIC ARTHRITIS (PSA) PATIENTS
https://doi.org/10.1136/annrheumdis-2019-eular.2464

SAT0367 PSAID9 IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH FILGOTINIB VS PLACEBO: RESULTS FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY
https://doi.org/10.1136/annrheumdis-2019-eular.5408

POS1038 THE EFFECT OF FILGOTINIB ON ENTHESITIS: 100-WEEK DATA FROM AN OPEN-LABEL EXTENSION STUDY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.884

POS1049 EFFECT OF FILGOTINIB ON PASDAS: DRIVERS OF LOW AND VERY LOW ACTIVITY UP TO WEEK 100
https://doi.org/10.1136/annrheumdis-2021-eular.1721

Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064

FRI0339 LONG-TERM EFFICACY OF THE ORAL SELECTIVE JANUS KINASE 1 INHIBITOR FILGOTINIB IN PSORIATIC ARTHRITIS: WEEK 52 RESPONSE PATTERNS IN INDIVIDUAL PATIENTS FROM AN OPEN-LABEL EXTENSION (OLE) STUDY (EQUATOR2)
https://doi.org/10.1136/annrheumdis-2020-eular.2624

OP0224 FILGOTINIB TREATMENT LEADS TO RAPID AND SUSTAINED REDUCTIONS IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2020-eular.4927

nct03101670 at ClinicalTrials.gov

Documents that mention this clinical trial

POS1037 CORRELATION BETWEEN SKIN INVOLVEMENT, JOINT INVOLVEMENT AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POST-HOC ANALYSIS OF EQUATOR/EQUATOR2
https://doi.org/10.1136/annrheumdis-2021-eular.883

SAT0373 EFFECT OF FILGOTINIB ON PATIENT-REPORTED OUTCOMES IN ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY
https://doi.org/10.1136/annrheumdis-2019-eular.6108

FRI0343 EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR)
https://doi.org/10.1136/annrheumdis-2020-eular.2495

Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial
https://doi.org/10.1136/rmdopen-2023-003550

OP0109 EFFICACY OF FILGOTINIB VS PLACEBO IN ACTIVE PSORIATIC ARTHRITIS: PATIENT-LEVEL DATA FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY
https://doi.org/10.1136/annrheumdis-2019-eular.6064

THU0031 FILGOTINIB TREATMENT PROVIDES RAPID AND SUSTAINED REDUCTION OF INFLAMMATORY BIOMARKERS IN MODERATE TO SEVERE PSORIATIC ARTHRITIS (PSA) PATIENTS
https://doi.org/10.1136/annrheumdis-2019-eular.2464

SAT0367 PSAID9 IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH FILGOTINIB VS PLACEBO: RESULTS FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY
https://doi.org/10.1136/annrheumdis-2019-eular.5408

POS1038 THE EFFECT OF FILGOTINIB ON ENTHESITIS: 100-WEEK DATA FROM AN OPEN-LABEL EXTENSION STUDY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.884

POS1049 EFFECT OF FILGOTINIB ON PASDAS: DRIVERS OF LOW AND VERY LOW ACTIVITY UP TO WEEK 100
https://doi.org/10.1136/annrheumdis-2021-eular.1721

Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064

FRI0339 LONG-TERM EFFICACY OF THE ORAL SELECTIVE JANUS KINASE 1 INHIBITOR FILGOTINIB IN PSORIATIC ARTHRITIS: WEEK 52 RESPONSE PATTERNS IN INDIVIDUAL PATIENTS FROM AN OPEN-LABEL EXTENSION (OLE) STUDY (EQUATOR2)
https://doi.org/10.1136/annrheumdis-2020-eular.2624

OP0224 FILGOTINIB TREATMENT LEADS TO RAPID AND SUSTAINED REDUCTIONS IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2020-eular.4927

nct03101670 at ClinicalTrials.gov

Documents that mention this clinical trial

POS1037 CORRELATION BETWEEN SKIN INVOLVEMENT, JOINT INVOLVEMENT AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POST-HOC ANALYSIS OF EQUATOR/EQUATOR2
https://doi.org/10.1136/annrheumdis-2021-eular.883

SAT0373 EFFECT OF FILGOTINIB ON PATIENT-REPORTED OUTCOMES IN ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY
https://doi.org/10.1136/annrheumdis-2019-eular.6108

FRI0343 EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR)
https://doi.org/10.1136/annrheumdis-2020-eular.2495

Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial
https://doi.org/10.1136/rmdopen-2023-003550

OP0109 EFFICACY OF FILGOTINIB VS PLACEBO IN ACTIVE PSORIATIC ARTHRITIS: PATIENT-LEVEL DATA FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY
https://doi.org/10.1136/annrheumdis-2019-eular.6064

THU0031 FILGOTINIB TREATMENT PROVIDES RAPID AND SUSTAINED REDUCTION OF INFLAMMATORY BIOMARKERS IN MODERATE TO SEVERE PSORIATIC ARTHRITIS (PSA) PATIENTS
https://doi.org/10.1136/annrheumdis-2019-eular.2464

SAT0367 PSAID9 IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH FILGOTINIB VS PLACEBO: RESULTS FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY
https://doi.org/10.1136/annrheumdis-2019-eular.5408

POS1038 THE EFFECT OF FILGOTINIB ON ENTHESITIS: 100-WEEK DATA FROM AN OPEN-LABEL EXTENSION STUDY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.884

POS1049 EFFECT OF FILGOTINIB ON PASDAS: DRIVERS OF LOW AND VERY LOW ACTIVITY UP TO WEEK 100
https://doi.org/10.1136/annrheumdis-2021-eular.1721

Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064

FRI0339 LONG-TERM EFFICACY OF THE ORAL SELECTIVE JANUS KINASE 1 INHIBITOR FILGOTINIB IN PSORIATIC ARTHRITIS: WEEK 52 RESPONSE PATTERNS IN INDIVIDUAL PATIENTS FROM AN OPEN-LABEL EXTENSION (OLE) STUDY (EQUATOR2)
https://doi.org/10.1136/annrheumdis-2020-eular.2624

OP0224 FILGOTINIB TREATMENT LEADS TO RAPID AND SUSTAINED REDUCTIONS IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2020-eular.4927
Funding

Funding for this research was provided by:

Galápagos

Gilead Sciences
License Information

License valid from 2023-11-09